Analysts forecast that Catalent Inc (NYSE:CTLT) will post $0.29 earnings per share for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Catalent’s earnings, with the lowest EPS estimate coming in at $0.24 and the highest estimate coming in at $0.35. Catalent posted earnings per share of $0.21 during the same quarter last year, which indicates a positive year over year growth rate of 38.1%. The firm is expected to report its next earnings results before the market opens on Tuesday, November 6th.
According to Zacks, analysts expect that Catalent will report full-year earnings of $1.88 per share for the current year, with EPS estimates ranging from $1.85 to $1.92. For the next fiscal year, analysts forecast that the firm will post earnings of $2.09 per share, with EPS estimates ranging from $1.95 to $2.21. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Catalent.
Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, August 28th. The company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.06. The firm had revenue of $685.30 million during the quarter, compared to analyst estimates of $690.69 million. Catalent had a net margin of 3.39% and a return on equity of 20.42%. The business’s revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.65 earnings per share.
A number of analysts have recently issued reports on CTLT shares. JPMorgan Chase & Co. boosted their target price on shares of Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Wednesday, August 29th. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. UBS Group started coverage on shares of Catalent in a research note on Tuesday. They set a “neutral” rating and a $48.00 target price for the company. Finally, ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $49.33.
Shares of CTLT traded down $0.02 during trading hours on Friday, reaching $41.47. 976,559 shares of the company traded hands, compared to its average volume of 947,037. The firm has a market capitalization of $6.61 billion, a P/E ratio of 26.08, a P/E/G ratio of 2.71 and a beta of 1.40. Catalent has a 12-month low of $36.73 and a 12-month high of $47.87. The company has a current ratio of 2.15, a quick ratio of 1.79 and a debt-to-equity ratio of 2.44.
In other Catalent news, Director Donald E. Morel, Jr. acquired 10,000 shares of the stock in a transaction that occurred on Thursday, September 13th. The stock was bought at an average cost of $43.00 per share, with a total value of $430,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John R. Chiminski sold 130,545 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $45.32, for a total transaction of $5,916,299.40. The disclosure for this sale can be found here. 1.40% of the stock is owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the stock. California Public Employees Retirement System raised its holdings in Catalent by 18.3% in the first quarter. California Public Employees Retirement System now owns 260,552 shares of the company’s stock worth $10,698,000 after purchasing an additional 40,267 shares in the last quarter. Sei Investments Co. raised its holdings in Catalent by 11.2% in the first quarter. Sei Investments Co. now owns 138,071 shares of the company’s stock worth $5,669,000 after purchasing an additional 13,956 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Catalent by 1.8% in the first quarter. Principal Financial Group Inc. now owns 581,638 shares of the company’s stock worth $23,882,000 after purchasing an additional 10,249 shares in the last quarter. Northwestern Mutual Investment Management Company LLC raised its holdings in Catalent by 56.8% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 27,280 shares of the company’s stock worth $1,120,000 after purchasing an additional 9,880 shares in the last quarter. Finally, Blair William & Co. IL bought a new position in Catalent in the first quarter worth about $657,000. 91.76% of the stock is owned by institutional investors.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: Determine Your Level of Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.